IPO Year: 2022
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|
424B3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
10-Q - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
10-K/A - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
10-Q/A - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
SC 13G/A - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)
SC 13G - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)
GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has entered into agreements with two additional site locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. Four of the planned six trial sites are now prepared to enroll patients in the clinical trial, including the UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, Allegheny Health Network (AHN)
GAITHERSBURG, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the issuance of U.S. Patent No. 12,077,515, titled "Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease." This patent was officially issued on September 3, 2024, further strengthening Shuttle Pharma's intellectual property portfolio and supporting its ongoing efforts to develop novel therapeutics targeting histone deacetylase (HDAC) enzymes. The newly issued patent covers a series of selective HDAC inhibitors designed to
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2024. Shuttle Pharma's recent highlights include the following: Enrollment of patients in the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma has recently opened following the entry of agreements with two site locations to administer t
GAITHERSBURG, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Rule. Nasdaq sent notice to the Company that it had regained compliance as of August 27, 2024, after it traded above $1.00 per share for ten consecutive trading days. About Shuttle Pharmaceuticals Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma
GAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today reports that it received formal notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq") that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the "Q2 Quarterly Report"). The Company's non-compliance with the Listing Rule resulted
GAITHERSBURG, Md., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has entered into agreements with two of the six site locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. Site initiation visits have been completed for two sites. The trial is now open to enroll patients in the clinical trial. Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with
GAITHERSBURG, Md., July 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript reporting on the ability of one of the Company's HDAC inhibitor pre-clinical assets, SP-1-303, which exhibits ataxia-telangiectasia mutated protein (ATM) activation and modulation of estrogen receptor expression resulting in substantial growth inhibition of estrogen receptor positive breast cancer cells (ER + BC). The published manuscript, titled "Dual-targeting cla
GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of Timothy Lorber, CPA, as the Company Chief Financial Officer. The Company's current Chief Financial Officer, Michael Vander Hoek, who also serves as our Vice President, Regulatory, will be transitioning out of his role as Chief Financial Officer and will assume the Vice President, Regulatory position on a full-time basis. Mr. Lorber is a CPA with more than 40 years of profession
GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that Dr. Anatoly Dritschilo, Chief Executive Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024. Dr. Dritschilo's presentation will include an update on the Company's progress toward clinical and scientific milestones of its Phase 2 Clinical Trial of Ropidoxuridine
GAITHERSBURG, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the first quarter ended March 31, 2024. Recent Highlights Shuttle Pharma's recent highlights include the following: Received FDA approval to proceed with the Phase 2 Clinical Trial of Ropidoxuridine for treatment of patients with glioblastoma, a deadly malignancy of the brain with no known cure.Received centra
3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)
4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)
4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)
4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)
4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)
4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)
4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)
GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of Timothy Lorber, CPA, as the Company Chief Financial Officer. The Company's current Chief Financial Officer, Michael Vander Hoek, who also serves as our Vice President, Regulatory, will be transitioning out of his role as Chief Financial Officer and will assume the Vice President, Regulatory position on a full-time basis. Mr. Lorber is a CPA with more than 40 years of profession
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript reporting on the ability of one of the Company's HDAC inhibitor pre-clinical assets, SP-1-303, which exhibits ataxia-telangiectasia mutated protein (ATM) activation and modulation of estrogen receptor expression resulting in substantial growth inhibition of estrogen receptor positive breast cancer cells (ER + BC). The published manuscript, titled "Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, prefere
Gainers Reshape Lifesciences (NASDAQ:RSLS) shares rose 88.9% to $0.39 during Tuesday's after-market session. The market value of their outstanding shares is at $9.2 million. Dermata Therapeutics (NASDAQ:DRMA) stock rose 12.8% to $3.7. The company's market cap stands at $1.6 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) stock moved upwards by 7.88% to $0.47. The company's market cap stands at $7.8 million. Ocular Therapeutix (NASDAQ:OCUL) shares rose 7.25% to $6.36. The market value of their outstanding shares is at $985.0 million. Unicycive Therapeutics (NASDAQ:UNCY) shares rose 6.02% to $0.89. The company's market cap stands at $33.4 million. Virios Therapeutics (NASDAQ:VIRI) shares
Shuttle Pharmaceuticals (NASDAQ:SHPH) reported quarterly losses of $(0.10) per share. This is a 42.86 percent decrease over losses of $(0.07) per share from the same period last year.
Shares of Macatawa Bank Corporation (NASDAQ:MCBC) rose sharply in today’s pre-market trading after Wintrust Financial Corporation (NASDAQ:WFTC) and Macatawa Bank announced that they have entered into a definitive merger agreement for Wintrust to acquire Macatawa in an all-stock transaction. Macatawa Bank shares jumped 37% to $13.60 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Dynatronics Corporation (NASDAQ:DYNT) shares rose 69.8% to $0.6301 in pre-market trading after dipping over 5% on Monday. Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) gained 55% to $0.6974 in pre-market trading after the company posted a profit for the fourth quarter.
Gainers Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 33.9% to $0.83 during Friday's after-market session. The market value of their outstanding shares is at $3.2 million. Masimo (NASDAQ:MASI) shares rose 12.48% to $151.77. The company's market cap stands at $8.0 billion. Vicarious Surgical (NYSE:RBOT) shares moved upwards by 11.17% to $0.38. The market value of their outstanding shares is at $66.7 million. Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 11.11% to $2.2. The company's market cap stands at $8.0 million. Psyence Biomedical (NASDAQ:PBM) stock increased by 9.09% to $1.2. The company's market cap stands at $16.0 million. Bright Green (NASDAQ:BGXX) shares ro
Shuttle Pharmaceuticals (NASDAQ:SHPH) reported quarterly losses of $(0.11) per share. This is a 83.33 percent decrease over losses of $(0.06) per share from the same period last year.
https://register.epo.org/application?number=EP19738394
Gainers Inspire Veterinary (NASDAQ:IVP) stock moved upwards by 37.5% to $0.26 during Thursday's after-market session. The market value of their outstanding shares is at $2.8 million. Tharimmune (NASDAQ:THAR) stock rose 16.5% to $0.53. The market value of their outstanding shares is at $1.3 million. MyMD Pharmaceuticals (NASDAQ:MYMD) shares increased by 8.28% to $0.18. The company's market cap stands at $9.1 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) stock increased by 8.2% to $0.43. The market value of their outstanding shares is at $6.9 million. Windtree Therapeutics (NASDAQ:WINT) stock rose 6.12% to $0.47. The company's market cap stands at $3.0 million. BiomX (AMEX:PHGE) shares
Gainers Sagimet Biosciences (NASDAQ:SGMT) stock rose 103.5% to $13.88 during Monday's regular session. The company's market cap stands at $317.8 million. Bullfrog AI Hldgs (NASDAQ:BFRG) shares moved upwards by 41.1% to $6.9. The market value of their outstanding shares is at $42.0 million. Bone Biologics (NASDAQ:BBLG) shares increased by 32.3% to $4.3. The market value of their outstanding shares is at $2.2 million. 60 Degrees (NASDAQ:SXTP) stock moved upwards by 26.19% to $0.79. The company's market cap stands at $4.5 million. AquaBounty Techs (NASDAQ:AQB) stock rose 25.65% to $2.4. The company's market cap stands at $9.2 million. BIMI Intl Medical (NASDAQ:BIMI) shares increased by 22